On November 15, 2017 Moderna in collaboration with Merck (product and $200M funding) announced their first-in-human dosing of their KEYNOTE-603 Phase 1 clinical trial using mRNA-4157, and mRNA gene therapy product which they refered to as a “personaised cancer vaccine“. [1, 2]
